Prerna Mewawalla, Associate Professor at Drexel University, shared a post on X:
“My VuMedi presentation from Tandem2025 is live!
We explore real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma from the USMIRC study—highlighting the feasibility of CAR-T & bispecifics post-BCMA exposure.
Key insights from our research:
- Sequential BCMA therapy remains feasible and effective.
- No significant difference in PFS between CAR-T and bispecifics following Belantamab.
- Prior BCMA exposure did not predict poor outcomes.
Would love to hear your experiences with BCMA sequencing in practice—how are you approaching it?
Watch here.”